A presentation of the first quantitative clinical study completed with 5-MeO-DMT-Containing toad bufotoxin in human subjects conducted at an ibogaine treatment center in Mexico. This study compares scores on the Mystical Experiences Questionnaire (MEQ) from 5-MeO-DMT-Containing toad bufotoxin experiences to the scores from the Johns Hopkins study done with psilocybin and smoking cessation. In the Johns Hopkins study, those individuals who reported having mystical experiences were also among the group who had greatest success with smoking cessation. As such, this study suggests that 5-MeO-DMT holds potential for treating addiction disorders as it similarly produces mystical experiences as psilocybin. The presentation will include some of the most notable results from the study and considerations for future investigation.
